Table 1: Platinum continuing neoadjuvant chemotherapy for advanced vulvar cancer.

Author, Year	Patients	Chemotherapy Regimen	Activity
Achilli 2012 [20]	1	CISPLATIN 40mg/m2 d TOPOTECAN 2mg/m21	+
Aragona 2012 [22]	12	CISPLATIN 50mg/m2 d1 5-FLUOROURACIL 800mg/m2 d1-4	+
	6	CISPLATIN 50mg/m2 d2,3 PACLITAXEL 175mg/m2 d1	+
	6	CISPLATIN 50mg/m2 d2,3 PACLITAXEL 175mg/m2 d1 5-FLUOROURACIL 800mg/m2 d1-4	+
	6	CISPLATIN 50mg/m2 d1 VINCRISTINE 1mg/m2 d1-3 BLEOMYCIN 25U/m2 d1-3	+
Han 2012 [17]	6	PACLITAXEL 60mg/m2 CARBOPLATIN 2.7 AUC	_
Domingues 2010 [21]	5	PACLITAXEL 100mg/m2 d1 weekly	+
	10	CISPLATIN 60-80mg/m2 5-FLUOROURACIL 750mg/m2 d1-4	+
Benedetti-Panici 1993 [16]	21	CISPLATIN 100mg/m2 d1 BLEOMYCIN 15mg d1 and d8 METHOTREXATE 300mg/m2 d8	+
Geisler 2006 [15]	10	CISPLATIN 50mg/m2 d1 5-FLUOROURACIL 1000mg/m2 d1-4	+
Shimizu 1990 [19]	1	CISPLATIN 66.7mg/m2 d6 BLEOMYCIN 5U d1-6 VINCRISTINE 1mg d6 MITOMYCIN C 10mg d6	+
Current study	3	PACLITAXEL 175mg/m2 CARBOPLATIN 5.0 AUC	+

AUC: Area Under The Curve, qd: Every Day